Overview

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Status:
Completed
Trial end date:
2024-03-05
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.
Phase:
Phase 3
Details
Lead Sponsor:
LEO Pharma